$BNGO Simon really doesn't know when it comes to Saphyr. I've read his twitter posts and he doesn't have the full picture. He bases a lot of his reasoning based on stuff he researched last year. I don't think he's read any of the multiple published studies this year. Here's one he doesn't understand. Since the medical field is recommending genome analysis to be used at determining if a person has a predisposition to a certain condition/disease, wouldn't you want to scan the largest area possible for the cheapest cost? That is a broad market in clinical use. If a structural variant is found, then they can do additional testing on that specific area of the SV. Or is my analysis wrong with this?